Effects of Intravesical Instillation of Cyclooxygenase-2 Inhibitor on Cyclophosphamide-induced Overactive Bladder.
- Author:
Joon JANG
1
;
Joon Chul KIM
;
Yoon Bo LEE
;
Seong Il SEO
;
Yong Hyun PARK
;
Tae Kon HWANG
Author Information
1. Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea. kjc@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Cyclooxygenase-2 inhibitors;
Bladder;
Cyclophosphamide
- MeSH:
Administration, Intravesical*;
Cyclooxygenase 2 Inhibitors;
Cyclooxygenase 2*;
Cyclophosphamide;
Rats, Sprague-Dawley;
Urinary Bladder;
Urinary Bladder, Overactive*;
Weights and Measures
- From:Korean Journal of Urology
2004;45(12):1241-1245
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was performed to investigate the effects of intravesical instillation of cyclooxygenase-2 (COX-2) inhibitors on the cyclophosphamide-induced overactive bladder. MATERIALS AND METHODS: The 40 Sprague-Dawley rats were divided into 3 groups; the control group, the overactive group, and the COX-2 inhibitor treated group. Cystometrograms (CMG) were performed and the contraction interval, inter-contraction interval, contraction time and contraction pressure were measured. After CMG, the bladders of each group were dissected out, and weighed. RESULTS: On CMG, the contraction interval and inter-contraction interval for the overactive group were significantly decreased compared with the control group. After treatment with COX-2 inhibitor, the contraction interval and inter-contraction interval were significantly increased compared with the overactive group (p<0.05). The contraction time in the overactive group was significantly increased compared with the control group, and it was also decreased in the COX-2 inhibitor treated group compared with the overactive group (p<0.05). The contraction pressure in the overactive group and the COX-2 inhibitor treated group were significantly increased compared with the control group. There were no significant differences between the overactive and COX-2 inhibitor treated groups. The bladder weights of the overactive and COX-2 inhibitor treated groups were significantly increased compared with the control group (p<0.05). CONCLUSIONS: Intravesical instillation of COX-2 inhibitor can suppress cyclophosphamide-induced detrusor overactivity. Therefore, intravesical instillation of COX-2 inhibitor may be considered as a possible treatment for the overactive bladder.
